MAIA Biotechnology
thio trial patients dosed to date | MAIA Biotechnology
Company
Deck Type
Sector
Industry
Deck date
July 2023
Slide
12 of 35
Similar slides by MAIA Biotechnology
See diffirences between slides (animation)
Investor Presentation
January 2024
thio trial patients dosed to date | MAIA Biotechnology
Investor Presentation
November 2023
thio trial patients dosed to date | MAIA Biotechnology
Investor Presentation
October 2023
thio trial patients dosed to date | MAIA Biotechnology
Related slides by other companies
Avenue Therapeutics
IPO
October 2022
safety and efficacy has been demonstrated in two phase trials in over patients | Avenue Therapeutics
ATAI
Investor Presentation
October 2023
demonstrated a rapid and dose dependent effect along with a safety profile phase study trial design results summary | ATAI
Ocuphire Pharma
Results
October 2022
has the potential to be first line of therapy for patients efficacy signal safety non invasive treatment option guidance physician patients efficacy signal safety non invasive treatment option | Ocuphire Pharma
ATAI
Investor Presentation
January 2024
demonstrated a rapid and dose dependent effect along with a safety profile target engagement demonstrated safe well tolerated sedation comparable to placebo phase study trial design results summary | ATAI
Other recent decks by MAIA Biotechnology
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
October 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights